Wuxi AppTec CoWUXIF 84 Days Payable is 38.82 as of Mar. 2026, which is 45% above its 10-year median of 26.83. GuruFocus rates WUXIF with a GF Score™ of 84/100 and a GF Value™ of $11.26 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks worse than 75.26% on this metric.
The historical rank and industry rank for Wuxi AppTec Co's Days Payable or its related term are showing as below:
WUXIF'
s Days Payable Range Over the Past 10 Years
Min: 22.95 Med: 26.83 Max: 35.92
Current: 35.76
During the past 12 years, Wuxi AppTec Co's highest Days Payable was 35.92. The lowest was 22.95. And the median was 26.83.
WUXIF's Days Payable is ranked worse than 75.26% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs WUXIF: 35.76
Wuxi AppTec Co's Days Payable
increased
from Mar. 2025 (32.54) to Mar. 2026 (38.82).
It may suggest that Wuxi AppTec Codelayed paying its suppliers.
Wuxi AppTec Co Days Payable Related Terms
Wuxi AppTec Co Days Payable Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Wuxi AppTec Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a Days Payable of 38.82 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wuxi AppTec Co and its competitors. This is 45% above median its historical median of 26.83. Over the past decade, Wuxi AppTec Co's Days Payable has ranged from 22.95 to 35.92. According to the industry distribution chart, Wuxi AppTec Co ranks #143 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 75.3%.
Is Wuxi AppTec Co's Days Payable too high?
Wuxi AppTec Co's current Days Payable of 38.82 is 45% above median its 10-year median of 26.83. Over the past 10 years, this metric has ranged from a low of 22.95 to a high of 35.92. The Medical Diagnostics & Research industry median Days Payable is 67.28. Wuxi AppTec Co's value of 38.82 is 42.3% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #143 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #143 out of 190 companies for Days Payable. This places Wuxi AppTec Co in the lower half of its industry. The industry median Days Payable is 67.28. Wuxi AppTec Co's value of 38.82 is 42.3% below this benchmark. Historically, Wuxi AppTec Co's own Days Payable has ranged from 22.95 to 35.92 over the past decade. While the company's 10-year median is 26.83 vs. the industry median of 67.28, Wuxi AppTec Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Days Payable of 38.82 is 42.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Days Payable is 38.82, which is 45% above median its own 10-year median of 26.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.26, compared to a current price of $15.63 — trading 38.8% above its estimated fair value. The current Days Payable is 38.82, which is 45% above median its 10-year median of 26.83 and 42.3% below the Medical Diagnostics & Research industry median of 67.28. Wuxi AppTec Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Days Payable is 38.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $15.63 is trading 38.8% above its estimated GF Value™ of $11.26.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Days Payable: 38.82 (45% above median its 10-year median of 26.83)
GF Value™: $11.26 vs. price of $15.63 (38.8% above fair value)
Industry Position: 42.3% below the Medical Diagnostics & Research median (#143 of 190)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
84GF Score
Get the complete analysis for WUXIF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
